Diagnostics major Metropolis Healthcare has announced the acquisition of Ambika Pathology Laboratory, a Kolhapur-based pathology chain, for ₹17 crore. The deal includes a deferred payment of ₹1.7 crore, structured under a business transfer agreement.
Strengthening Regional Presence
Ambika Pathology runs a central laboratory in Kolhapur along with 12 patient touchpoints, offering a broad portfolio of diagnostic tests. Nearly 75% of its revenue comes from walk-in B2C customers, reflecting its strong retail presence in the region.
With this acquisition, Metropolis aims to transform Ambika into a mini reference lab, catering to Kolhapur and surrounding districts in western Maharashtra. The move is part of Metropolis’ “string-of-pearls” growth strategy, which focuses on building regional diagnostic clusters through targeted acquisitions.
Recent Growth Strategy
This is the fourth acquisition in the last 10 months for Metropolis, underscoring its aggressive expansion plan. The company said the integration of Ambika’s operations will enhance productivity and profitability across its existing network in Maharashtra.
Maharashtra is already Metropolis’ largest market, contributing nearly 40% of overall revenue. By strengthening its footprint in western Maharashtra, the company expects to capture greater market share in one of India’s most competitive diagnostics hubs.
Financial Snapshot
Ambika Pathology reported a turnover of ₹7.96 crore in FY25, making it a strong regional player with high local brand equity. For Metropolis, the acquisition represents both scale and synergy, consolidating its position as a leading diagnostics provider in India.
Keep building. Keep learning. Keep growing with StartupByDoc.